Synonyms: compound 1 [WO2023196910]
Compound class:
Synthetic organic
Comment: The chemical structure for neladalkib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as an anaplastic lymphoma kinase (ALK) inhibitor with potential antineoplastic action. It is claimed in Nuvalent's patent WO2023196910 [1]. Nuvalent's pipeline declares one ALK inhibitor, NVL-655, so we suspect that this may be neladalkib.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Green JA, Kropp JT, Noci D, Pelish HE, Porter JR, Soglia JR, Tangpeerachaikul A, Turner CD, Zhu VW, Perason DJ. (2023)
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine. Patent number: WO2023196910A1. Assignee: Nuvalent, Inc. Priority date: 06/04/2023. Publication date: 12/10/2023. |